Format

Send to

Choose Destination
Breast Cancer Res Treat. 2018 Feb;167(3):719-729. doi: 10.1007/s10549-017-4554-4. Epub 2017 Nov 6.

The effect of an aerobic exercise bout 24 h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms: a RCT.

Author information

1
Department of Biomedical Engineering, University of Alberta, 1098-8308 114 St, Edmonton, T6G 2V2, Canada.
2
Centre for Heart, Lung and Vascular Health, University of British Columbia, 360 - 1147 Research Road, Kelowna, V1V 1V7, Canada.
3
Cardiff Centre for Exercise and Health, Cardiff Metropolitan University, Cyncoed Campus, Cyncoed Rd, Cardiff, CF23 6XD, UK.
4
Rehabilitation Sciences, University of British Columbia, 212-2177 Wesbrook Mall, Vancouver, V6T 1Z3, Canada.
5
School of Kinesiology, University of British Columbia, 6081 University Blvd, Vancouver, V6T 1Z1, Canada.
6
Medical Oncology, British Columbia Cancer Agency, 600 W 10th Ave, Vancouver, V5Z 4E6, Canada.
7
Department of Medicine, Gordon & Leslie Diamond Health Care Centre 9th Floor, University of British Columbia, 2775 Laurel Street, Vancouver, V5Z 1M9, Canada.
8
Columbia University Medical Center, 630 West 168th St, New York, 10032, USA.
9
Department of Physical Therapy, University of British Columbia, 212-2177 Wesbrook Mall, Vancouver, V6T 1Z3, Canada. Kristin.Campbell@ubc.ca.

Abstract

PURPOSE:

In rodents, a single exercise bout performed 24 h prior to a single doxorubicin treatment provides cardio-protection. This study investigated whether performing this intervention prior to every doxorubicin treatment for breast cancer reduced subclinical cardiotoxicity and treatment symptoms.

METHODS:

Twenty-four women with early stage breast cancer were randomly assigned to perform a 30-min, vigorous-intensity treadmill bout 24 h prior to each of four doxorubicin-containing chemotherapy treatments or to usual care. Established echocardiographic and circulating biomarkers of subclinical cardiotoxicity, as well as blood pressure and body weight were measured before the first and 7-14 days after the last treatment. The Rotterdam symptom checklist was used to assess patient-reported symptoms.

RESULTS:

The exercise and usual care groups did not differ in the doxorubicin-related change in longitudinal strain, twist, or cardiac troponin. However, the four total exercise bouts prevented changes in hemodynamics (increased cardiac output, resting heart rate, decreased systemic vascular resistance, p < 0.01) and reduced body weight gain, prevalence of depressed mood, sore muscles, and low back pain after the last treatment (p < 0.05) relative to the usual care group. No adverse events occurred.

CONCLUSIONS:

An exercise bout performed 24 h prior to every doxorubicin treatment did not have an effect on markers of subclinical cardiotoxicity, but had a positive systemic effect on hemodynamics, musculoskeletal symptoms, mood, and body weight in women with breast cancer. A single exercise bout prior to chemotherapy treatments may be a simple clinical modality to reduce symptoms and weight gain among women with breast cancer.

KEYWORDS:

Breast cancer; Cardiotoxicity; Doxorubicin; Exercise; Treatment symptoms

PMID:
29110150
DOI:
10.1007/s10549-017-4554-4
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center